Scarica l'app Stockscreener
47.89
1.82%
-0.89
Dopo l'orario di chiusura:
47.53
-0.36
-0.75%
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity Biosciences Insider Sold Shares Worth $1,003,058, According to a Recent SEC Filing - MarketScreener
Avidity Biosciences Executive Sells 20,000 Shares - TradingView
Avidity Biosciences Form 4: 20,000 options exercised at $22.34 - Stock Titan
Facioscapulohumeral Muscular Dystrophy Market Analysis Report 2025-2035: Innovations from Leading Players Such as Avidity Biosciences, F. Hoffman-La Roche, Epicrispr, and Fulcrum Fuel ExpansionResearchAndMarkets.com - The AI Journal
Will FDA Feedback and Del-Zota BLA Timeline Shift Redefine Avidity Biosciences' (RNA) Late-Stage Pipeline? - Yahoo Finance
How Avidity Biosciences Inc. stock performs in weak economyPortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Can Avidity Biosciences Inc. stock beat market expectations this quarterMarket Trend Report & AI Driven Price Forecasts - newser.com
Will a bounce in Avidity Biosciences Inc. offer an exitTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota - MSN
What momentum shifts mean for Avidity Biosciences Inc.Insider Buying & Reliable Breakout Forecasts - newser.com
Oct 21 panel: Avidity Biosciences to speak at Chardan Conference; webcast available 11:00 PT - Stock Titan
Sector ETF performance correlation with Avidity Biosciences Inc.Trade Ideas & Weekly Top Gainers Trade List - newser.com
Forecasting Avidity Biosciences Inc. price range with options data2025 EndofYear Setup & High Return Stock Watch Alerts - newser.com
Using R and stats models for Avidity Biosciences Inc. forecasting2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Avidity Biosciences Inc (RNA) Technical Analysis - TipRanks
What Makes Avidity Biosciences (RNA) an Investment Choice? - MSN
[8-K] – Avidity Biosciences, Inc. (RNA) (CIK 0001599901) | RNA SEC FilingForm 8-K - Stock Titan
Avidity Biosciences Delays Biologics License Application - TipRanks
Avidity Biosciences Updates BLA Submission Timeline for Del-Zota - TradingView
[8-K] Avidity Biosciences, Inc. Reports Material Event | RNA SEC FilingForm 8-K - Stock Titan
Avidity Biosciences delays DMD drug submission to Q1 2026 By Investing.com - Investing.com Nigeria
Avidity rises on plans to submit muscle wasting drug application to US FDA - TradingView
Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission - MarketScreener
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 - Investing News Network
Avidity Biosciences delays DMD drug submission to Q1 2026 - Investing.com India
Avidity Biosciences announces positive pre-BLA meeting with US FDA for del-zota in DMD44 - MarketScreener
2025-10-13 | Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | NDAQ:RNA | Press Release - Stockhouse
How Avidity Biosciences Inc. stock compares to growth peersQuarterly Profit Review & Safe Entry Trade Reports - newser.com
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 36.85% Potential Upside in Innovative RNA Therapeutics - DirectorsTalk Interviews
Chart based exit strategy for Avidity Biosciences Inc.Market Growth Review & Low Risk Entry Point Tips - newser.com
Avidity Biosciences, Inc.Common Stock (NQ: - FinancialContent
Avidity Biosciences Inc. stock daily chart insightsGap Down & Weekly Top Performers Watchlists - newser.com
Can Avidity Biosciences Inc. stock hit record highs againPortfolio Value Report & Low Risk High Win Rate Stock Picks - newser.com
Avidity Biosciences (NASDAQ:RNA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Ranking Avidity Biosciences Inc. among high performing stocks via toolsWeekly Stock Recap & Weekly High Momentum Picks - newser.com
Is Avidity Biosciences Inc a good long term investmentMid Cap Growth Trends & Low Entry Capital Stocks - earlytimes.in
What drives Ball Corporation stock priceBlue Chip Stock Analysis & High Return Trading Portfolio - earlytimes.in
Avidity Biosciences’ Phase 2 Study on AOC 1001: A Potential Game-Changer for DM1 Treatment - TipRanks
Avidity Biosciences (NASDAQ:RNA) Insider Eric Mosbrooker Sells 6,562 Shares - MarketBeat
RNA Officer Exercises Options at $9.05 and Sells 6,562 Shares - Stock Titan
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - BioSpace
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):